Position statement on nicotinamide use for glaucoma neuroprotection - 2025 - American Glaucoma Society and American Academy of Ophthalmology

Position statement on nicotinamide use for glaucoma neuroprotection - 2025 - American Glaucoma Society and American Academy of Ophthalmology

Glaucoma is the most common neurodegenerative disease and the leading cause of irreversible blindness globally, with a projected worldwide prevalence expected to affect 111.8 million people by 2040. While conventional intraocular pressure (IOP)-lowering therapy for glaucoma can effectively slow or halt the disease, many patients continue to experience optic nerve damage and visual field loss even when IOP reduction has been substantial. There is a strong unmet need for neuroprotective, IOP-independent agents that can both slow retinal ganglion cell damage (neuroprotection) and potentially heal damaged retinal ganglion cells (neurorecovery, neuroregeneration), as was identified in a 2022 American Glaucoma Society Position Paper and elsewhere.


Read full Guideline